在美的控股之前，万东医疗控制权曾几经更迭。 上任8个月后，万东医疗董事长辞职。 1月26日，万东医疗（600055.SH）发布公告称，公司董事长马赤兵因个人原因辞去公司一切职务，离 任后，马赤兵将不在公司及控股子公司任职。董事会对其在任期间的履职表示感谢。 与此同时，美的集团（000333.SZ、0300.HK）核心高管王建国被选举为新任董事长，任期自公司第十 届董事会第十三次会议审议通过之日起至公司第十届董事会任期届满之日止。资料显示，王建国现任美 的集团执行董事、执行总裁，并同时兼任集团新能源事业部总裁、美的医疗总裁等要职。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源 | 野马财经 作者丨孙梦圆 截至1月28日，万东医疗报收16.16元/股，总市值113.6亿元。 图源：罐头图库 五年换三帅 自2021年美的集团成为万东医疗控股股东以来，公司董事长已三度更迭。 首任"美的系"掌门人胡自强，职业生涯涵盖GE、三星等跨国公司，曾任无锡小天鹅副总经理，后在美 的集团历任中央研究院院长、副总裁兼首席技术官（CTO）。2021年中，本已准备退休的胡自强，应集 团战略需要转而出任万 ...

"美的系"马赤兵上任7个月后，万东医疗（600055）一纸公告，又换董事长了，此次，美的集团（000333）执行董事王建国亲自坐阵。 1月26日，万东医疗公告，公司董事会于近日收到公司董事长马赤兵提交的书面辞职报告。马赤兵因个人原因申请辞去公司董事长、董事、董事会战略委 员会成员及召集人、董事会薪酬与考核委员会成员职务。离任后，马赤兵将不在公司及控股子公司任职。 2021年，美的集团收购万东医疗29.09%的股份，成为其控股股东。此后，万东医疗立足"数智化医疗生态构建者"战略定位，形成覆盖"高端设备研发—智 能服务网络—医疗资源普惠"三位一体的业务体系，持续推动国产医疗装备产业升级。 不过，自2021年后，万东医疗业绩整体走下坡路。2021年～2022年，万东医疗归母净利润分别为1.83亿元、1.75亿元，连续两年出现下滑。2023年，公司 业绩虽短暂回升，但2024年再度陷入增收不增利。 根据万东医疗历史公告，马赤兵任职董事长仅7个月。 2025年5月21日，公司召开第十届董事会第八次会议，审议通过了《关于选举董事长的议案》，同意选举马赤兵为第十届董事会董事长。 据万东医疗披露的简历，马赤兵曾任美的集团微清 ...

近日，万东医疗（600055）发布公告称，公司董事长马赤兵因个人原因于2026年1月25日辞去董事长、 董事及其他相关职务同时，公司于2026年1月26日召开董事会，选举王建国为新任董事长，任期自会议 审议通过之日起至董事会任期届满。 王建国拥有丰富的管理经验，曾在美的集团（000333）担任多个高管职务，现任美的集团执行董事及执 行总裁等。 ...

Group 1 - Company Sanwei Communication announced a partnership to establish a private equity fund with a total investment of 114 million yuan, with the company contributing 25 million yuan, focusing on high-tech industries such as smart manufacturing and new energy [1] - Zijin Mining plans to acquire 100% of Allied Gold Corporation for approximately 280 billion yuan, with core assets including gold mines in Mali and Ivory Coast, and an expected increase in gold production to 25 tons by 2029 [2] - Haike New Source signed a long-term cooperation agreement with BYD Lithium Battery to supply at least 100,000 tons of solvents annually for three years [3] Group 2 - China Aluminum International reported a new contract total of 468.36 billion yuan for 2025, a year-on-year increase of 51.94%, with significant growth in industrial and overseas contracts [4] - Jianxin Co. expects a net loss of 20 to 29 million yuan for 2025, compared to a profit of 19.37 million yuan in the previous year [5] - ST Dongjing anticipates a loss of 40 to 60 million yuan for 2025, an improvement from a loss of 73.45 million yuan in the previous year [6] Group 3 - Zhejiang Haideman plans to raise up to 1.517 billion yuan through a private placement for high-end machine tool projects [7] - Anlu Technology intends to raise up to 1.262 billion yuan for FPGA chip development projects [8][9] - AVIC Chengfei expects a net profit increase of 5.47% to 11.67% for 2025, projecting profits between 3.4 billion and 3.6 billion yuan [10] Group 4 - Hengtong Technology forecasts a net profit increase of 82.95% to 110.05% for 2025, with expected profits between 270 million and 310 million yuan [11] - Qingmu Technology anticipates a net profit increase of 30% to 50% for 2025, projecting profits between 118 million and 136 million yuan [13] - Zhongke Microelectronics expects a loss of 18 to 25 million yuan for 2025, marking a shift from profit to loss [14] Group 5 - Huashan Electric predicts a loss of 42 to 49.2 million yuan for 2025, compared to a loss of 26.77 million yuan in the previous year [15] - Qitian Technology expects a loss of 60 to 95 million yuan for 2025, an improvement from a loss of 214 million yuan in the previous year [16] - Sanyuan Gene announced a plan to reduce its shareholding by up to 2% [17] Group 6 - Zhongxing Junye forecasts a net profit increase of 134.32% to 173.37% for 2025, with expected profits between 300 million and 350 million yuan [18] - Shengshi Technology anticipates a net profit decrease of 50.26% to 64.55% for 2025, projecting profits between 62 million and 87 million yuan [19] - Lante Optical expects a net profit increase of 70.04% to 81.38% for 2025, with projected profits between 375 million and 400 million yuan [20] Group 7 - Dongfang Risen anticipates a loss of 2.3 to 2.9 billion yuan for 2025, compared to a loss of 3.436 billion yuan in the previous year [21] - Wandong Medical announced a change in leadership, electing Wang Jianguo as the new chairman [22] - Longsoft Technology expects a loss of 49 to 60 million yuan for 2025, with projected revenues between 148 million and 164 million yuan [23] Group 8 - Zongyi Co. forecasts a net profit increase of approximately 264.05% for 2025, with expected revenues of around 480 million yuan [24] - Sifang New Materials anticipates a loss of around 300 million yuan for 2025, with projected revenues of about 1 billion yuan [25] - Jiuding New Materials plans to acquire 100% of Jiuding New Energy for 39.51 million yuan [26] Group 9 - Kangyuan Pharmaceutical received approval for clinical trials of a new drug aimed at treating children's ailments [27] - Kaipu Testing announced plans for share reductions by its chairman and vice president [28] - Fengfan Co. intends to acquire 51% of Yanling Jiaye for 382.5 million yuan, with performance commitments for the next three years [29][30] Group 10 - Axin Security received a government subsidy of 6.8 million yuan [31] - Ge Microelectronics announced plans for a share reduction by a major shareholder [32] - ST Yingfit expects a loss of 24 to 31 million yuan for 2025, a reduction from a loss of 40.4 million yuan in the previous year [33] Group 11 - Fujilai forecasts a net profit increase of 282.17% to 296.8% for 2025, with expected profits between 62.7 million and 65.1 million yuan [34] - Huakong Saige anticipates a loss of 97 to 120 million yuan for 2025, a shift from a profit of 17.03 million yuan in the previous year [35] - Landun Optical expects a loss of 70 to 95 million yuan for 2025, compared to a profit of 6.49 million yuan in the previous year [36] Group 12 - ST Zhongji forecasts a loss of 35 to 55 million yuan for 2025, compared to a loss of 231 million yuan in the previous year [37] - Zhongsheng Pharmaceutical expects a profit of 260 to 310 million yuan for 2025, reversing a loss of 299 million yuan in the previous year [38] - Youkeshu reported a net loss of 13.85 million yuan for the first three quarters of 2025 [39] Group 13 - Haosheng Electronics anticipates a net profit decrease of 56.85% to 59.77% for 2025, projecting profits between 69 million and 74 million yuan [40] - Xiangyuan Cultural Tourism plans to withdraw from a low-altitude economic investment fund [41] - Guoen Co. has set a preliminary price range of 34 to 42 HKD for its H-share issuance [42]

Core Viewpoint - The recent leadership change at Wandong Medical involves the resignation of Chairman Ma Chibing after only seven months, with Wang Jianguo, an executive from Midea Group, taking over as the new chairman [1][3]. Group 1: Leadership Changes - Ma Chibing submitted his resignation due to personal reasons, stepping down from multiple roles including Chairman and member of various committees [1][2]. - Wang Jianguo, the new chairman, has a long history with Midea Group, having held various senior positions since 1999 [4]. Group 2: Company Performance - Wandong Medical's performance has been declining, with net profits of 183 million yuan in 2021 and 175 million yuan in 2022, indicating a downward trend [4]. - In the first three quarters of 2025, the company reported revenues of 1.189 billion yuan, an increase of 8.73% year-on-year, but faced a net loss of 27.21 million yuan, a decline of 123.51% [4]. Group 3: Profitability Metrics - The company's gross margin has been under pressure, with a gross margin of 32.62% in the first three quarters of 2025, continuing a downward trend from 45.82% in 2021 to 36.55% in 2024 [5][6]. - The gross margin figures for the years 2021 to 2024 were 45.82%, 44.11%, 42.07%, and 36.55%, respectively, showing a consistent decline [5][6].

北京万东医疗科技股份有限公司 第十届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 北京万东医疗科技股份有限公司（以下简称"公司"）第十届董事会第十三次会议于2026年1月26日以通 讯表决方式召开。本次会议的会议通知及相关资料于2026年1月21日以电子邮件的方式向全体董事发 出。会议应到董事8人，实到8人，公司高管人员列席会议。本次会议的召开符合《公司法》和《公司章 程》的规定，所作决议合法有效。 依据《公司章程》规定，会议由董事共同推举王建国先生主持，形成如下决议： 一、审议通过《关于选举董事长的议案》。 选举王建国先生为公司第十届董事会董事长。具体内容详见公司披露于上海证券交易所网站的（2026- 008）《万东医疗关于董事长离任暨选举董事长的公告》。 本议案表决结果：同意8票，反对0票，弃权0票。 证券代码：600055 证券简称：万东医疗 公告编号：2026-007 二、审议通过《关于调整第十届董事会部分专门委员会成员的议案》。 为完善公司治理结构，保证董事会专门委员会能够顺利高效开展工 ...

证券日报网讯 1月26日，万东医疗发布公告称，公司董事会于近日收到公司董事长马赤兵先生提交的书 面辞职报告。马赤兵先生因个人原因申请辞去公司董事长、董事、董事会战略委员会成员及召集人、董 事会薪酬与考核委员会成员职务。离任后，马赤兵先生将不在公司及控股子公司任职。2026年1月26 日，公司召开第十届董事会第十三次会议，审议通过了《关于选举董事长的议案》，选举王建国先生为 第十届董事会董事长，任期自公司第十届董事会第十三次会议审议通过之日起至公司第十届董事会任期 届满之日止。 （文章来源：证券日报） ...

北京商报讯（记者 丁宁）1月26日晚间，万东医疗（600055）发布公告称，公司董事会于近日收到公司 董事长马赤兵提交的书面辞职报告。马赤兵因个人原因申请辞去公司董事长、董事、董事会战略委员会 成员及召集人、董事会薪酬与考核委员会成员职务。离任后，马赤兵将不在公司及控股子公司任职。 万东医疗表示，1月26日，公司召开第十届董事会第十三次会议，审议通过了《关于选举董事长的议 案》，选举王建国为第十届董事会董事长，任期自公司第十届董事会第十三次会议审议通过之日起至公 司第十届董事会任期届满之日止。 简历显示，王建国，1999年加入美的集团，曾任家用空调事业部供应链管理部总监、行政与人力资源部 总监、冰箱事业部总经理、美的国际总裁、智能家居事业群总裁等职务，现任美的集团执行董事、执行 总裁、新能源事业部总裁、美的医疗总裁、锐珂医疗总裁、广东美的制冷设备有限公司董事长、万东医 疗董事长。 ...

人民财讯1月26日电，万东医疗（600055）1月26日公告，董事长马赤兵因个人原因申请辞去公司董事 长、董事、董事会战略委员会成员及召集人、董事会薪酬与考核委员会成员职务。离任后，马赤兵将不 在公司及控股子公司任职。1月26日，公司召开第十届董事会第十三次会议，选举王建国为第十届董事 会董事长，任期自公司第十届董事会第十三次会议审议通过之日起至公司第十届董事会任期届满之日 止。 ...

（记者 王晓波） 每经AI快讯，万东医疗1月26日晚间发布公告称，公司第十届第十三次董事会会议于2026年1月26日以 通讯表决方式召开。会议审议了《关于选举董事长的议案》等文件。 每日经济新闻 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 ...